Réponse plaquettaire inadaptée au clopidogrel et vasculopathie périphérique

Abstract

Platelet inhibition by aspirin or clopidogrel plays a crucial role in the prevention of atherothrombotic events in
patients with peripheral arterial disease. However, insufficient platelet inhibition by clopidogrel is described in a large
proportion of the treated patients. Higher loading or maintenance doses of clopidogrel, prasugrel, addition of cilostazol enable to restore adequate platelet inhibition. While the
benefit of « aggressive » anti-platelet therapy is well documented during percutaneous coronary angioplasty, this
strategy needs to be evaluate in patients with peripheral
arterial disease.